Anxiety disorders (ADs), namely generalized anxiety disorder (GAD), panic disorder (PD), and phobias, are relatively common, often disabling conditions with lifetime prevalence of over 20% (Kessler *et al*, 2005). Family and twin studies suggest both genetic and environmental factors underlying their etiology, with moderate levels of familial aggregation (OR 3--6) and heritability (30--50%) ([@R1]). As with most complex genetic traits, many linkage and candidate gene association studies of ADs have been conducted, with little success in robustly identifying their susceptibility genes ([@R2];[@R3]).

Genome-wide association studies (GWAS) have proven to be a successful method for the identification of common genetic variants that increase susceptibility to complex disease. Recently, GWAS of specific anxiety and related disorders such as PD ([@R4];[@R5]), post-traumatic stress disorder ([@R6]--[@R8]), obsessive compulsive disorder ([@R9];[@R10]), and phobias ([@R11]) have been published. However, these have been limited by small sample sizes and resulting low overall power to detect significant associations.

Despite differing on diagnostic definitions based upon clinical presentation, ADs likely represent various expressions of an underlying common diathesis of abnormal regulation of basic threat-response systems ([@R12]). ADs exhibit strong lifetime comorbidity with each other ([@R13]), with genetic epidemiologic studies pointing to shared genetic risk factors between them ([@R14];[@R15]). Since clinical descriptions do not reflect underlying genetic architecture, traditional studies focused on individual ADs may not represent an effective study design for such phenotypes. A more informative approach would coordinate data from clusters of disorders with shared genetic risk factors ([@R16]). One such strategy is to model a latent anxiety liability factor indexing ADs with substantial genetic overlap. Also, for common disorders like ADs, disease states can be interpreted as extremes of continuous liability dimensions, as has been done for somatic illnesses like obesity and hypertension. Therefore, quantitative trait approaches, assuming a continuous liability distribution, can be used to construct informative latent psychiatric phenotypes ([@R17]). Analyzing AD phenotypes in a coordinated manner may represent a powerful approach for identifying susceptibility genes for ADs. This strategy has yielded some success, as demonstrated by prior reports from our group ([@R18]).

In the current study, we conducted genome-wide association analyses in nine large, independent samples. To identify genetic variants contributing to genetic susceptibility shared across the ADs, we applied two phenotypic approaches: (1) categorical case-control comparisons based upon having any AD diagnosis, and (2) quantitative phenotypic factor scores derived from a multivariate analysis combining information across the clinical phenotypes. We performed a meta-analysis for each phenotype across the nine samples for over 18 000 unrelated individuals using around 6.5 million imputed SNPs. This represents the largest genetic study to date of any of the ADs and the first of this magnitude to explicitly incorporate comorbidity structure directly into prediction of SNP effects.

Materials and Methods {#S1}
=====================

Overview {#S2}
--------

We conducted parallel GWAS in nine samples of European ancestry and combined the results via meta-analysis. We applied two phenotypic strategies aimed at capturing common (pleiotropic) genetic effects shared across the five core ADs: GAD, PD, social phobia, agoraphobia, and specific phobias. We conducted two types of analyses in each sample based upon complementary approaches to modeling the comorbidity and common genetic risk across the ADs: (1) case-control (CC) comparisons, in which cases were designated as having "any AD" versus supernormal controls, and (2) quantitative factor scores (FS) estimated for every subject in the sample using confirmatory factor analysis.

Samples {#S3}
-------

Nine samples containing AD phenotypes from seven independent studies participating in the Anxiety NeuroGenetics STudy (ANGST) Consortium were included in the meta-analysis. Standardized assessment instruments were used to generate DSM-based AD diagnoses, with some exceptions. The samples were genotyped on various SNP arrays according to their original study designs. Genotype calling, quality control (QC), imputation, and association analyses were performed at each site under similar standard protocols. SNP imputation was conducted within each sample using IMPUTE2 ([@R19]) or MACH ([@R20]) software utilizing the full 1000 Genomes Project reference data (March 2012, release v3). Genomic locations were based on NCBI build 37/UCSC hg 19 data. After imputation, SNPs with MAF\<0.01, poor imputation quality \<0.30, and Hardy-Weinberg equilibrium p-value \<10^−6^ were removed. See [Supplement](#SD1){ref-type="supplementary-material"} for study descriptions and [Supplemental Table S1](#SD1){ref-type="supplementary-material"} for details of genotyping and QC procedures. [Table 1](#T1){ref-type="table"} summarizes basic statistics by cohort.

Genome-wide association analyses {#S4}
--------------------------------

To identify genetic variants contributing to genetic susceptibility shared across the ADs, we applied and compared two complementary phenotypic approaches: (1) categorical CC comparisons, and (2) quantitative phenotypic FS. For CC comparisons, AD cases were assigned to subjects meeting criteria for any lifetime AD (ANX=2) while control subjects were "super-normal", i.e., having few or no clinical anxiety symptoms (ANX=0); those with subsyndromal ADs (ANX=1) were excluded from the CC analyses. For FS analyses, first exploratory factor analyses were conducted using Mplus (version 4) ([@R39]) separately in each sample, finding evidence for a single common factor model by scree plots. This was followed by confirmatory factor analyses that estimated a single FS for each subject from this common AD liability factor. (See [Supplement](#SD1){ref-type="supplementary-material"} for details of phenotype construction.) Association analyses were then performed in each study independently with imputed SNP dosages under an additive genetic model using logistic regression for CC phenotype and linear regression for quantitative FS phenotype. As covariates, we used sex and age at interview, as they were significant predictors of the phenotypes. Ancestry principal components were estimated for each sample and included on a sample-by-sample basis depending on their correlation with the outcome phenotypes. The quantile-quantile (Q-Q) plot was used to evaluate overall significance of the association test results and the genomic control factor λ.

Meta-analysis of GWAS {#S5}
---------------------

We performed an inverse-variance weighted, fixed-effects meta-analysis with all GWAS samples using METAL ([@R21]) (nine samples using CC phenotypes and eight using FS phenotypes). For each SNP, a pooled effect size, standard error, and p-value were computed. SNPs with low MAF (\<0.05) were excluded, resulting in a final meta-analytic data set of around 6.5M SNPs. Cochran's *Q* statistics and corresponding *I*^2^ statistics were used as heterogeneity metrics. Cochran's *Q* statistic was computed by summing the squared deviations of each study's estimate by weighting each study's contribution in the same manner as in the meta-analyses. *I*^2^ measured the amount of heterogeneity that is not due to chance.

Q-Q and Manhattan plots were examined, and False Discovery Rate (FDR) q-values were calculated based on the p-values from the meta-analyses. Q-values provide a balance between type I and Type II errors and can be interpreted as the probability that a marker identified as significant is a false discovery ([@R22]).

Cross-validation {#S6}
----------------

In order to examine overall consistency of association between datasets, we employed a leave-one-out procedure for internal cross-validation. At each step, we meta-analyzed eight of the nine CC GWAS samples as the "training" set (seven of the eight samples were used for FS), the results of which were then tested in the respective remaining target sample ("testing" set). The top associated SNPs in the training set (P~training~\<1×10^−5^, pruned to r^2^\<0.4 within a 500-kb window) were used to test the replicability (P~testing~\<0.05) and consistency of the direction of their effects with the top associated SNPs identified in each testing set. One thousand random permutations of phenotype allocation to an individual's genome-wide genotypes were performed in each training-testing set pair, totaling 9,000 and 8,000 permutations in CC and FS, respectively. Across all sets, we compared the aggregate numbers of replicated SNPs and SNPs with the same direction of effect against the numbers expected by chance.

Gene-based tests {#S7}
----------------

The SNP-based p-values derived from the meta-analyses were applied to gene-based association testing using KGG software (<http://statgenpro.psychiatry.hku.hk/limx/kgg/>) ([@R23]). No prioritization or preselection of genes was performed. Gene-based tests in KGG combine univariate association statistics to evaluate the cumulative evidence of association in a gene using extended Simes test (GATES) ([@R24]). SNPs were mapped onto 23 931 genes according to the gene coordinate information from NCBI, and SNPs within 10-kb of each gene were assigned to that gene. We considered genes with P\<2×10^−6^ (=.05/23 931) as significant and those with q-value \<0.1 as interesting ([@R25]).

Secondary Analyses {#S8}
------------------

We conducted several secondary analyses, the details of which are described in the [Supplement](#SD1){ref-type="supplementary-material"}.

1.  SNP-based Heritability. Genomic-relatedness-matrix restricted maximum likelihood (GREML), as implemented in the software program GCTA ([@R26]), was conducted in our largest cohort (RS) to estimate the total amount of variance explained by all analyzed SNPs. This was supplemented by a similar procedure in the full meta-analytic sample using LD score regression ([@R27]).

2.  Polygenic Risk Profile Analyses. Given the observed high comorbidity between ADs and other psychiatric syndromes, genomic profile risk scores (GPRS) ([@R28]) were estimated to test the additive joint effects of multiple variants between our AD GWAS data as target samples and summary data from Psychiatric Genomics Consortium phase 1 (PGC1) schizophrenia (SCZ), bipolar disorder (BIP), and MDD as discovery samples.

RESULTS {#S9}
=======

GWAS Meta-analysis {#S10}
------------------

We performed an inverse-variance weighted, fixed-effects meta-analysis with all discovery GWAS data including approximately 6.5M common SNPs after applying post-imputation QC to each study. The genomic inflation factor λ ranged from 0.990 to 1.038 for all studies. The Q-Q plots of the meta-analyses for the CC and FS phenotypes are presented in [Figure 1](#F1){ref-type="fig"}. Meta-analytic inflation factors were 1.03 and 1.02, suggesting little effect of population stratification. Manhattan plots are presented in [Figure 2](#F2){ref-type="fig"}. [Table 2](#T2){ref-type="table"} lists the LD-independent, genome-wide significant SNPs and associated regions. For the CC model, the strongest association was observed at rs1709393 located in an intron of an uncharacterized non-coding RNA locus *LOC152225* on chromosome 3q12.3 (P=1.65×10^−8^; Q=0.027). Allelic frequencies were very similar across studies and ranged between 0.55 and 0.60. The most significant SNP in the FS model was rs1067327 on chromosome 2p21 within *CAMKMT* encoding the calmodulin-lysine N-methyltransferase (P=2.86×10^−9^; Q=0.0017) with LD extending into several adjacent genes. Allelic frequencies were consistent across studies, ranging from 0.32 to 0.36. Both of these SNPs were imputed with very high quality across studies (R^2^\>0.93). As indicted in the forest plots ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}), no heterogeneity of effects was observed for either SNP. [Figure 3](#F3){ref-type="fig"} displays the regional SNP plots for these two genome-wide significant loci.

Given that the CC and FS phenotypic approaches provide conceptually different but otherwise complementary information, we estimated the overlap in their association signals. These phenotypes were highly correlated in the different cohorts (0.88--0.94). Overall rank-based correlations between the CC and FS association effects were 0.61. The degree of correlation increased with decreasing p-value threshold, ranging from 0.275 to 0.899 ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). The most significant SNPs all have the same direction of effect (top 1,000 SNPs in CC and top 1,500 SNPs in FS); indeed, among the approximately 30% of total SNPs with opposite sign, none had even suggestively significant association (P\<1×10^−5^). However, among \~1.4M independent SNPS (pruned at r^2^=0.4), significantly more with P\<10^−5^ were identified for the FS phenotype than for the CC phenotype: 42 verses 18 (test p-value=0.0034).

Cross-Validation {#S11}
----------------

In the leave-one-out cross-validation analyses, the replication rate was significantly higher than expected by chance ([Table 3](#T3){ref-type="table"}). In CC, 18 of 173 tested SNPs across all leave-one out analyses replicated in the left out testing sets (permutation P=0.001) and the proportion of SNPs with the same direction of effect was 59.5% (sign test P=0.005). Of 315 tested SNPs in FS, 43 SNPs replicated (permutation P\<0.001) and 77.8% had the same direction of effect (sign test P\<0.001). [Supplemental Figure S2](#SD1){ref-type="supplementary-material"} displays Manhattan plots of the training set meta-analyses conducted after leaving out each sample.

Gene-based tests {#S12}
----------------

In the CC model, *LOC152225* on 3q12.3 surpassed genome-wide significance (P=1.19×10^−6^; Q=0.028). In the FS model, three genes exceeded genome-wide significance: *PREPL*, *CAMKMT*, and *SLC3A1* on chromosome 2 ([Table 4](#T4){ref-type="table"}). [Supplementary Figure S3](#SD1){ref-type="supplementary-material"} depicts the Manhattan plots for these gene-based analyses.

Secondary Analyses (see [Supplement](#SD1){ref-type="supplementary-material"} for details) {#S13}
------------------------------------------------------------------------------------------

1.  SNP-based heritability. This was estimated by GREML using GCTA in the Rotterdam sample as 0.106 (SE=0.06, P=0.05) for FS phenotype and 0.138 (SE=0.18, P=0.2) for CC phenotype on the liability scale assuming 10% AD population prevalence. Within the margin of error, these were consistent with LD score regression using summary statistics in the full meta-analysis sample, with SNP heritability estimated as 0.072 (SE=0.028) for FS phenotype and 0.095 (SE =0.037) for CC phenotype.

2.  Polygenic Risk Profile Analyses. GPRS from PGC-MDD explained a small but significant proportion of variance in CC ADs in QIMR (0.5%--0.7%), while SCZ and BIP each explained a somewhat smaller proportion of this variance varying by sample. These results were supported by LD score regression performed in the meta-analysis sample, estimating significant genetic correlation between ADs and MDD (r=0.68) but not between ADs and BIP or SCZ.

DISCUSSION {#S14}
==========

We conducted the largest and most comprehensive genetic study of the primary anxiety disorders (ADs) to date. Specifically, we integrated phenotypic information on GAD, PD, agoraphobia, social phobia, and specific phobias and combined this with genome-wide SNP data from nine large samples totaling over 18 000 subjects. We conducted parallel GWAS in these samples and statistically combined the results via meta-analysis, with the aim of detecting common variants that play a role in shared AD susceptibility.

While only an approximate representation of the underlying complexity of AD genetic mechanisms, our integrated phenotypic approaches successfully identified novel genetic variants that significantly associate with these composite AD phenotypes. The results were generally the same whether analyzing individual SNPs or genes. In the CC model, we identified a novel genome-wide association within an uncharacterized non-coding RNA locus *LOC152225* on chromosome 3q12.3. We found no extant reports for this locus in PubMed or the NHGRI Catalogue of Published GWAS ([www.genome.gov/gwastudies/](www.genome.gov/gwastudies/)). In the FS model, we detected genome-wide significant associations at SNPs in three genes within a large LD block on chromosome 2p21, each of which has reported expression in brain: (1) *SLC3A1* encoding the large subunit of a heterodimeric dibasic /neutral amino acid transporter (solute carrier family 3 (amino acid transporter heavy chain), member 1); (2) *PREPL* encoding a putative prolyl endopeptidase belonging to the prolyl oligopeptidase family; and (3) *CAMKMT* encoding a calmodulin-lysine N-methyltransferase. This region is well-known for two contiguous gene-deletion syndromes, the hypotonia-cystinuria syndrome and the more severe 2p21 deletion syndrome ([@R29]). Deletion of *SLC3A1* results in the autosomal-recessive form of cystinuria ([@R30]), while *PREPL* deletion causes hypotonia at birth, failure to thrive and growth hormone deficiency ([@R31]). The evolutionarily conserved class I protein methyltransferase encoded by *CAMKMT* acts in the formation of trimethyllysine in calmodulin which is involved in calcium-dependent signaling ([@R32]). Interestingly, GWAS of schizophrenia and bipolar disorder have highlighted other genes encoding proteins involved in calcium-dependent signaling ([@R33]). Although the most significant SNP, rs1067327, is located in an intron of *CAMKMT* , *in silico* analyses ([Supplement](#SD1){ref-type="supplementary-material"}) suggest rs698775 is the most likely functional candidate with a cis regulatory effect possibly specific to *PREPL*.

There is substantial phenotypic overlap between the CC and FS models used to capture the comorbidity and shared genetic risk among the ADs, and as expected, there was a high degree of concordance in the association signals genome-wide ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). The most significantly associated SNPs (p\<.0.05) have very high correlation of association effects, suggesting they are tapping into strongly related AD risk factors. We note that, overall, the FS phenotype identified a larger number of associated SNPs than the CC model. This is likely due to several reasons: (1) this approach combines disorder information to capture individual differences on an underlying latent AD liability; (2) for high prevalence disorders, quantitative variables generally have greater power for genetic association than categorical variables ([@R34];[@R35]); (3) the FS models generally involve larger sample sizes since they also include the subjects with subthreshold ADs (score=1); and (4) the FS model produces a phenotype that incorporates the observed relationship information (covariance) between the individual ADs. These findings support the use of quantitative phenotypic factors scores in future GWAS of comorbid psychiatric disorders assessed in the same individuals.

Several secondary analyses support our findings. First, we applied cross validation in the nine samples to examine the internal consistency of the results. We created sub-samples by iteratively removing the data of each of the individual samples and conducting meta-analysis with the remaining datasets. A highly significant proportion of the top results were consistently identified across these sub-analyses, suggesting the stability and validity of our findings. Next we estimated the genome-wide contribution via GREML and the complementary LD-score regression approach, producing generally consistent estimates of SNP heritability across samples included and methods applied. Similar to GWAS studies of many phenotypes ([@R36]), these estimates are substantially smaller than those predicted by twin studies of ADs. Finally, we tested the polygenic association between our results and those from other psychiatric disorders using GRPS, finding significant correlation of genetic risk between ADs and MDD but not between ADs and BIP or SCZ. The former result is consistent with large epidemiologic studies that report correlated genetic risk between ADs and MDD (see ([@R15]) for review) as well as a prior overlap seen for depression and anxiety scales ([@R37]).

A strength of this study is that we applied phenotypic strategies aimed at detecting genetic variants that play a central but non-specific role in AD susceptibility. This is counter to the approach taken in most psychiatric genetic studies which generally apply case-control comparisons for specific clinical diagnoses, sometimes followed by adjunct cross-disorder analyses. However, it has long been recognized that clinical nosology poorly reflects etiological mechanisms, with both genetic and environmental risk factors showing non-specific effects across disorders. ADs, despite their heterogeneous clinical presentations, likely represent various expressions of an underlying common diathesis of abnormal regulation of basic threat-response systems ([@R12]). Given the value of fear and anxiety for survival, there are likely sets of evolutionarily-conserved genes that regulate these basic biological responses. This is supported by twin studies that identify factors of common genetic risk across ADs in addition to disorder-specific genetic factors. With this in mind, we applied and compared two strategies for combining information across clinical phenotypes. The first is a simple CC approach, comparing cases defined as having "any AD" against supernormal controls. The second applied multivariate modeling of the covariation among the ADs using the common factor model to define a single continuous dimension of liability for which quantitative scores can be estimated for each subject. Our group has applied this approach in prior candidate gene association studies ([@R18]) and in a pilot GWAS in the MGS sample ([@R38]), but this is the first such application in a large GWAS meta-analysis. We note that this strategy is consistent with NIMH's Research Domain Criteria (RDoC) initiative, which aims to serve as a framework for new approaches to research on mental disorders based on fundamental dimensions that cut across traditional disorder categories and more closely align with mechanisms that underlie psychopathology at various biological levels from genes to neural circuits ([@R39]). Also important to note is that ADs not only share genetic risk factors amongst themselves but also with other internalizing phenotypes like MDD ([@R15]), obsessive compulsive disorder ([@R40]), and personality traits like neuroticism and extroversion ([@R41]). It will be important for future studies to examine this broader pleiotropic spectrum either through cross-disorder GWAS as previously conducted for other psychiatric conditions ([@R42]) or by including these additional traits directly in the phenotypic construction with the ADs. It is possible that, by including AD cases with comorbid MDD, the genetic overlap between these conditions has influenced our results.

Several potential limitations of this study should be noted. First, although the total sample size far exceeds those from prior AD genetic studies, it is still relatively underpowered to detect common genetic variants of small effect expected for the genetic architecture of such complex phenotypes ([@R37]). Second, not all samples provided the same level of phenotypic coverage; in particular, some subjects in QIMR were missing diagnostic data for GAD or specific phobia. While this can produce bias, our forest plots, tests for heterogeneity, and internal validation analyses suggest that this likely did not bias our results. Third, consent agreements for some of the sites did not allow for sharing of subject data, so GWAS analyses had to be conducted separately using a standardized procedure and combined via meta-analysis. While this has been shown to approximate the power obtained when using raw data via mega-analysis ([@R38]), we were limited in our ability to conduct additional post-hoc analyses such as GPRS and GREML that require the use of raw GWAS data. Reassuringly, results obtained by applying LD score regression to summary statistics from the total meta-analysis sample were consistent with those using raw data from select individual samples. Fourth, the results apply only to subjects of European-ancestry and might not generalize to individuals of other genetic and cultural backgrounds. Finally, we combined all data available at the time of this study into a single meta-analysis rather than divide into discovery and replication samples. This was necessary due to the large sample sizes required to detect small effects of genes involved in complex traits like ADs. Internal cross-validation supported the robustness of our results but do not substitute for replication in well-powered, independent samples. At this time, we are unaware of other large data sets that could be used for replication of our results.

In summary, this study has identified several potentially novel susceptibility loci that increase shared risk across the primary ADs. Future studies are needed to (1) further confirm these findings via independent replication, (2) increase the total sample size to enhance power to detect additional loci, and (3) identify loci associated specifically with each particular AD not accounted for by the pleiotropic effects targeted in this study.
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======================
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Quantile-quantile plots of meta-analysis results for (a) case-control and (b) factor score phenotypes. Observed association results of −log~10~P , after LD-pruning at r^2^ of 0.4, are plotted against the expected distribution under the null hypothesis of no association.
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Manhattan plots of meta-analysis results for (a) case-control and (b) factor score phenotypes. Red horizontal line indicates the genome-wide significant p-value 5×10^−8^; blue line indicates the suggestive p-value=1×10^−5^.
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Regional plots around most significant SNPs in (a) case-control and (b) factor score model.
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Contributing Cohorts

  Cohort                                 Country       Mean age (s.d.) at interview   N Phenotyped   N Cases (ANX=2)   N Controls (ANX=0)   N Analyzed (FS/CC)
  -------------------------------------- ------------- ------------------------------ -------------- ----------------- -------------------- --------------------
  MGS Controls ([@R43])                  USA           50.0 (16.4)                    2659           757               1059                 2009/1336
  PsyCoLaus ([@R44])                     Switzerland   50.9 (8.8)                     3575           1044              1351                 2887/1955
  RS ([@R45])                            Netherlands   66.5 (10.8)                    9686           1112              5459                 7832/5379
  SHIP ([@R46])                          Germany       55.4 (13.9)                    2279           581               890                  2026/1379
  QIMR ([@R47])                          Australia     41.3 (11.5)                    6147           1611              2544                 2277/2156
  TRAILS ([@R48])                        Netherlands   18.7 (0.7)                     1584           390               472                  1155/614
  NESDA ([@R49]) / NTR ([@R50];[@R51])   Netherlands   45.6 (14.2) /44.6 (12.7)       4491           1521              2970                 NA/4491
  Total                                                                               31 060         7016              14 745               18 186/17 310

Abbreviations: MGS, Molecular Genetics of Schizophrenia; RS, Rotterdam Study; SHIP, Study of Health in Pomerania; NESDA/NTR, The Netherlands Study of Depression and Anxiety / Netherlands Twin Registry; QIMR, Queensland Institute of Medical Research; TRAILS, Tracking Adolescents\' Individual Lives Survey; FS, Factor Score; CC, Case-Control.

###### 

Top association results for meta-analysis of SNP main effects for case-control and factor score phenotypes.

                                                             Association with Original Phenotype   Cross Phenotype[†](#TFN7){ref-type="table-fn"}                                         
  -------------------- ---- ------ --- --------------------- ------------------------------------- ------------------------------------------------ -------- ------------------- -------- --------
  ***Case-Control***                                                                                                                                                                      
  rs1709393            TC   0.58   3   101684480-101692234   0.860 (0.816-0.906)                   1.65e-8                                          0.027    \-\-\-\-\-\-\-\--   0.0342   −0.010
  ***Factor Score***                                                                                                                                                                      
  rs1067327            CG   0.34   2   44588941-44678648     0.028 (0.019-0.038)                   2.86e--9                                         0.0017   ++++++++            0.0002   1.123

Chr, chromosome; Frq, frequency of allele 1; CI, 95% confidence interval.

First allele is the reference allele, for which the effect is reported.

Position denotes the associated region surrounding the top SNP containing 1 or more genome-wide significant SNPs in LD (r^2^\>0.4) with the top SNP.

Effect size represents odds ratio for case control and regression coefficient for factor score.

Direction of association is provided for each study in the following order: RS1, RS2, RS3, NTR/NESDA, MGS, PsyColaus, SHIP, QIMR, and TRAILS for case-control; RS1, RS2, RS3, MGS, PsyColaus, SHIP, QIMR, and TRAILS for factor score. Plus (+) indicates the association between the SNP and the corresponding anxiety phenotype is positive. Minus (−) indicates a negative direction of association.

Shown are the association results of the top SNPs in the other phenotype, i.e., factor score results of rs1709393 and case-control results of rs1067327.

###### 

Results of leave-one-out cross-validation analyses

                                              Case-Control   Factor Score                                                                                                                                                                     
  ------------------------------------------- -------------- ------------------------------------------------------ ------------------------------------------------------- --------- ------------------------------------------------------- --------------------------------------------------------
  MGS                                         19             3                                                      10                                                      39        0                                                       25
  GSK                                         26             3                                                      12                                                      22        4                                                       11
  RS1                                         24             0                                                      13                                                      42        6                                                       36
  RS2                                         15             3                                                      9                                                       45        0                                                       33
  RS3                                         22             0                                                      10                                                      46        21                                                      35
  SHIP                                        24             0                                                      14                                                      40        10                                                      32
  NTR/NESDA[c](#TFN11){ref-type="table-fn"}   14             3                                                      13                                                      \-        \-                                                      \-
  QIMR                                        13             3                                                      9                                                       35        0                                                       32
  TRAILS                                      16             3                                                      13                                                      46        2                                                       41
  **OVERALL**                                 **173**        **18**[\*](#TFN8){ref-type="table-fn"} **(P=0.001)**   **103**[\*](#TFN8){ref-type="table-fn"} **(P=0.005)**   **315**   **43**[\*](#TFN8){ref-type="table-fn"} **(P\<0.001)**   **245**[\*](#TFN8){ref-type="table-fn"} **(P\<0.001)**

P\<0.05 thresholds applied for replication and sign tests; Replication and sign tests are conducted based on permutations with 9,000 iterations in case-control and 8,000 iterations in factor score phenotype under the null hypothesis of no association (1,000 iteration for each pair of training and testing sets).

The number of SNPs associated at P~training~\<1×10^−5^ with r^2^\<0.4 in the leave-one-out meta-analysis using N-1 training samples after removing one testing sample at a time.

Of the SNPs with P~training~\<1×10^−5^ in the meta-analysis of the N-1 training samples, the number of replicated SNPs with one-sided P~testing~\<0.05 in the left-out (testing) sample.

Only case-control phenotype is available for NTR/NESDA sample.

###### 

Top associated genes (Q \< 0.1) using gene-based tests

  Gene                 p-value[a](#TFN13){ref-type="table-fn"}   q-value   SNP[b](#TFN14){ref-type="table-fn"} with lowest P   Lowest P[c](#TFN15){ref-type="table-fn"}   Chr   Gene Feature
  -------------------- ----------------------------------------- --------- --------------------------------------------------- ------------------------------------------ ----- --------------
  ***Case-Control***                                                                                                                                                            
  *LOC152225*          **1.19E-06**                              0.028     rs1709393                                           1.65E-08                                   3     ncRNA
  ***Factor Score***                                                                                                                                                            
  *PREPL*              **5.61E-08**                              0.001     rs786618                                            6.99E-09                                   2     intronic
  *CAMKMT*             **3.15E-07**                              0.004     rs1067327                                           2.86E-09                                   2     intronic
  *SLC3A1*             **1.45E-06**                              0.012     rs1142523                                           1.44E-07                                   2     3'UTR
  *LBX1*               7.50E-06                                  0.045     rs11190870                                          9.79E-07                                   10    downstream
  *LBX1-AS1*           1.33E-05                                  0.064     rs594791                                            1.05E-06                                   10    upstream

We used LD pruning at r^2^ of 0.4 for gene-based tests. Boldface indicates genome-wide P \< 2×10^−6^.

Gene-based p-value (bolded genome-wide significant P\<2×10^−6^) .

Most significant SNP within the corresponding gene.

SNP-based p-value for the most significant SNP

[^1]: Indicates equal contributions
